Literature DB >> 27487563

The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death.

Peng-Hsu Chen1, Cheng-Kuei Chang2, Chwen-Ming Shih3, Chia-Hsiung Cheng3, Cheng-Wei Lin3, Chin-Cheng Lee4, Ann-Jeng Liu5, Kuo-Hao Ho6, Ku-Chung Chen7.   

Abstract

Xanthohumol (XN), a prenylated chalcone extracted from hop plant Humulus lupulus L. (Cannabaceae), has potential for cancer therapy, including gliomas. Micro (mi)RNAs are small noncoding RNAs that control gene expression. Several miRNAs have been identified to participate in regulating glioma development. However, no studies have demonstrated whether miRNA is involved in XN cytotoxicity resulting in glioma cell death. This study investigated the effects of XN-mediated miRNA expression in activating apoptotic pathways in glioblastoma U87 MG cells. First, we found that XN significantly reduced cell viability and induced apoptosis via pro-caspase-3/8 cleavage and poly(ADP ribose) polymerase (PARP) degradation. We also identified that pro-caspase-9 cleavage, Bcl2 family expression changes, mitochondrial dysfunction, and intracellular ROS generation also participated in XN-induced glioma cell death. With a microarray analysis, miR-204-3p was identified as the most upregulated miRNA induced by XN cytotoxicity. The extracellular signal-regulated kinase (ERK)/c-Fos pathway was validated to participate in XN-upregulated miR-204-3p expression. With a promoter assay and ChIP analysis, we found that c-Fos dose-dependently bound to the miR-204-3p gene promoter region. Furthermore, miR-204-3p levels decreased in several glioma cell lines compared to astrocytes. Overexpression of miR-204-3p enhanced glioma cell apoptosis. IGFBP2, an upregulated regulator of glioma proliferation, was validated by a TCGA analysis as a direct target gene of miR-204-3p. XN's inhibition of the IGFBP2/AKT/Bcl2 pathway via miR-204-3p targeting played a critical role in mediating glioma cell death. These results emphasized that the XN-mediated miR-204-3p network may provide novel therapeutic strategies for future glioblastoma therapy and drug development.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ERK/c-Fos pathway; Glioblastoma; IGFBP2; Xanthohumol; miR-204-3p

Mesh:

Substances:

Year:  2016        PMID: 27487563     DOI: 10.1016/j.neuropharm.2016.07.038

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  27 in total

1.  Xanthohumol inhibits proliferation of laryngeal squamous cell carcinoma.

Authors:  Yan Li; Kai Wang; Shankai Yin; Hongliang Zheng; Daliu Min
Journal:  Oncol Lett       Date:  2016-10-25       Impact factor: 2.967

Review 2.  SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy.

Authors:  Xiang Cheng; Jianying Li; Deliang Guo
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 3.  Noncoding RNA actions through IGFs and IGF binding proteins in cancer.

Authors:  Aidan Kerr; Robert C Baxter
Journal:  Oncogene       Date:  2022-05-21       Impact factor: 8.756

4.  A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer.

Authors:  Peide Huang; Fengyu Li; Zongchao Mo; Chunyu Geng; Fang Wen; Chunyan Zhang; Jia Guo; Song Wu; Lin Li; Nils Brünner; Jan Stenvang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 5.  Xanthohumol for Human Malignancies: Chemistry, Pharmacokinetics and Molecular Targets.

Authors:  Vancha Harish; Effi Haque; Magdalena Śmiech; Hiroaki Taniguchi; Sarah Jamieson; Devesh Tewari; Anupam Bishayee
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

6.  Xanthohumol-Induced Rat Glioma C6 Cells Death by Triggering Mitochondrial Stress.

Authors:  Shaozhi Hou; Yang Song; Di Sun; Shujun Zhu; Zhenhua Wang
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

7.  MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway.

Authors:  Yan Shu; Ligang Ren; Bo Xie; Zhen Liang; Jing Chen
Journal:  Oncotarget       Date:  2017-10-23

8.  A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells.

Authors:  Daniel Mendanha; Joana Vieira de Castro; Joana Moreira; Bruno M Costa; Honorina Cidade; Madalena Pinto; Helena Ferreira; Nuno M Neves
Journal:  Molecules       Date:  2021-06-03       Impact factor: 4.411

Review 9.  Two Worlds Colliding: The Interplay Between Natural Compounds and Non-Coding Transcripts in Cancer Therapy.

Authors:  Alexandru A Sabo; Maria Dudau; George L Constantin; Tudor C Pop; Christoph-M Geilfus; Alessio Naccarati; Mihnea P Dragomir
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

10.  IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis.

Authors:  Chin-Sheng Hung; Chien-Yu Huang; Chia-Hwa Lee; Wei-Yu Chen; Ming-Te Huang; Po-Li Wei; Yu-Jia Chang
Journal:  Oncotarget       Date:  2017-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.